Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Tata Stl 489.35 3.73
Tata Pow 93.75 3.19
Hindalco 163.20 1.75
Ntpc Ltd 149.95 1.90
Gail 529.15 3.83
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Shasun Pharmaceuticals Limited
Shasun Pharmaceuticals Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:524552NSE:SHASUNPHARBloomberg:SAPH@INReuters:SHAS.BO
Market Lot: 1Face Value: 2ISIN Demat: INE317A01028
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
19-AUG-14 Shasun Pharmaceuticals said on Tuesday that the company has granted 2,23,000 stock options under Employee Stock Option Plan (ESOP) 2012 to the employees exercisable into same number of equity shares of the company. 08-JUL-14 Shasun Pharmaceuticals has completed both USFDA and Mexican Cofepris (Mexican regulatory authority) inspection at its API facility at Cussalore Tamil Nadu, India. 30-MAY-14 Shasun Pharmaceuticals disclosed a ste...   More..
Business Profile Future Plans
CEO Talk
Shasun Chemicals and Drugs Ltd, while focusing on the bulk drugs business, expects increased contribution from the contract research business. The bulk drugs business, including the biotech sector, will continue to be its major focus in the years to come.   S. Vimal Kumar
One To One
Recent news
Latest News
Strides Arcolab approves merger with Shasun Pharma  -IRIS 29-Sep-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)
Net sales
Other Income
Total Income
Cost of goods sold
OPBDIT
PAT
Gross Block
Equity capital
EPS (Rs.)
DPS (Rs.)
BV (Rs.)
P/E range (x)
Debt / Equity (x)
Operating margin (% of OI)
Net margin (% of OI)
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
Not Available
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer